Details for: MECOM
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 53.35rCSI 92.27%PRS 32.5
-
CSI 38.71rCSI 54.88%PRS 38.24
-
CSI 32.66rCSI 32.59%PRS 35.66
-
CSI 31.58rCSI 80.11%PRS 32.43
-
CSI 28.01rCSI 35.97%PRS 37.25
-
CSI 21.87rCSI 20.35%PRS 40.88
-
CSI 17.37rCSI 44.92%PRS 37.48
-
CSI 16.76rCSI 22.9%PRS 43.64
-
CSI 15.7rCSI 34.56%PRS 44.74
-
CSI 14.72rCSI 43.67%PRS 52.43
-
CSI 14.08rCSI 17.14%PRS 48.34
-
CSI 13.57rCSI 14.21%PRS 38.53
-
CSI 13.43rCSI 54.76%PRS 53.14
-
CSI 13.21rCSI 63.24%PRS 42.99
-
CSI 13.17rCSI 26.72%PRS 25.06
-
CSI 12.99rCSI 30.96%PRS 43.47
-
CSI 12.46rCSI 14.39%PRS 35.84
-
CSI 12.44rCSI 29.66%PRS 58.56
-
CSI 12.36rCSI 33.04%PRS 34.66
-
CSI 11.66rCSI 10.53%PRS 37.74
-
CSI 10.68rCSI 10.3%PRS 32.34
-
CSI 10.47rCSI 25.57%PRS 37.55
-
CSI 10.22rCSI 10.66%PRS 41.58
-
CSI 10.05rCSI 14.42%PRS 33.16
-
CSI 9.82rCSI 10.53%PRS 38.96
-
CSI 9.81rCSI 14.38%PRS 74.51
-
CSI 9.65rCSI 61.74%PRS 60.5
-
CSI 9.59rCSI 17.57%PRS 65.39
-
CSI 9.58rCSI 25.83%PRS 49.79
-
CSI 9.43rCSI 50.13%PRS 41.76
-
CSI 9.37rCSI 66.25%PRS 36.45
-
CSI 9.34rCSI 13.47%PRS 54.67
-
CSI 9.27rCSI 16.25%PRS 34.05
-
CSI 9.25rCSI 8.13%PRS 31.12
-
CSI 9.21rCSI 44.12%PRS 39.46
-
CSI 9.21rCSI 7.63%PRS 39.56
-
CSI 9.18rCSI 37.05%PRS 39.66
-
CSI 9.14rCSI 23.83%PRS 40
-
CSI 8.59rCSI 46.99%PRS 45.33
-
CSI 8.49rCSI 9.02%PRS 56.27
-
CSI 8.44rCSI 8.12%PRS 41.61
-
CSI 8.34rCSI 13.51%PRS 39.75
-
CSI 7.94rCSI 15.14%PRS 57.54
-
CSI 7.72rCSI 24.71%PRS 38.15
-
CSI 7.58rCSI 10.52%PRS 40.6
-
CSI 7.56rCSI 38.03%PRS 51.44
-
CSI 7.42rCSI 7.76%PRS 40.71
-
CSI 7.33rCSI 9.97%PRS 53.59
-
CSI 7.19rCSI 20.44%PRS 41.08
-
CSI 7.15rCSI 23.26%PRS 43.63
-
CSI 6.38rCSI 33.5%PRS 56.1
-
CSI 6.29rCSI 44.89%PRS 47.69
-
CSI 6.18rCSI 17.02%PRS 38.07
-
CSI 6.17rCSI 8.25%PRS 49.12
-
CSI 6.05rCSI 7.02%PRS 51.85
-
CSI 5.95rCSI 9.49%PRS 44.43
-
CSI 5.75rCSI 9.18%PRS 35.41
-
CSI 5.71rCSI 4.42%PRS 41.24
-
CSI 5.69rCSI 28.04%PRS 52.28
-
CSI 5.67rCSI 13.21%PRS 67.3
-
CSI 5.3rCSI 7.76%PRS 43.79
-
CSI 5.29rCSI 14.84%PRS 55.67
-
CSI 5.27rCSI 4.68%PRS 40.26
-
CSI 5.2rCSI 6.91%PRS 45.34
-
CSI 4.97rCSI 10.86%PRS 60.95
-
CSI 4.96rCSI 12.27%PRS 39.14
-
CSI 4.87rCSI 3.24%PRS 45.02
-
CSI 4.7rCSI 49.81%PRS 42.94
-
CSI 4.67rCSI 13.78%PRS 40.17
-
CSI 4.65rCSI 7.48%PRS 28.76
-
CSI 4.54rCSI 16.12%PRS 54.33
-
CSI 4.42rCSI 5.11%PRS 31.89
-
CSI 4.26rCSI 9.55%PRS 27.36
-
CSI 4.25rCSI 36.74%PRS 43.57
-
CSI 4.1rCSI 4.81%PRS 44.83
-
CSI 4.06rCSI 8.42%PRS 39.26
-
CSI 4.03rCSI 9.19%PRS 39.89
-
CSI 3.94rCSI 7.39%PRS 61.05
-
CSI 3.81rCSI 4.74%PRS 43.58
-
CSI 3.76rCSI 6.71%PRS 56.69
-
CSI 3.7rCSI 14.08%PRS 35.45
-
CSI 3.67rCSI 9.33%PRS 37.67
-
CSI 3.65rCSI 5.35%PRS 51.72
-
CSI 3.39rCSI 15.06%PRS 39.62
-
CSI 3.38rCSI 9.72%PRS 67.75
-
CSI 3.27rCSI 3.58%PRS 44.74
-
CSI 3.21rCSI 6.84%PRS 55.99
-
CSI 3.18rCSI 45.63%PRS 74.52
-
CSI 3.17rCSI 8.22%PRS 46.39
-
CSI 3.04rCSI 16.85%PRS 65.84
-
CSI 3rCSI 4.59%PRS 41.54
-
CSI 2.85rCSI 3.95%PRS 46.64
-
CSI 2.84rCSI 5%PRS 49.27
-
CSI 2.82rCSI 4.13%PRS 41.13
-
CSI 2.78rCSI 6.62%PRS 53.41
-
CSI 2.74rCSI 4.36%PRS 34.84
-
CSI 2.59rCSI 19.41%PRS 61.26
-
CSI 2.58rCSI 15.2%PRS 27.98
-
CSI 2.48rCSI 2.34%PRS 42.19
-
CSI 2.45rCSI 5.84%PRS 51.88
-
CSI 0.1rCSI 1.1%PRS 62.0%
-
CSI 0.3rCSI 7.0%PRS 69.0%
-
CSI 0.4rCSI 2.5%PRS 59.9%
-
CSI 0.5rCSI 7.4%PRS 70.9%
-
CSI 0.5rCSI 4.5%PRS 71.6%
-
CSI 0.7rCSI 0.9%PRS 45.6%
-
CSI 0.7rCSI 3.1%PRS 60.4%
-
CSI 0.8rCSI 2.3%PRS 42.1%
-
CSI 0.8rCSI 3.3%PRS 62.8%
-
CSI 0.9rCSI 6.7%PRS 67.9%
-
CSI 1.0rCSI 6.9%PRS 75.3%
-
CSI 1.0rCSI 14.3%PRS 72.3%
-
CSI 1.0rCSI 21.0%PRS 85.1%
-
CSI 1.1rCSI 7.6%PRS 66.1%
-
CSI 1.1rCSI 10.8%PRS 68.4%
-
CSI 1.1rCSI 2.4%PRS 50.8%
-
CSI 1.2rCSI 6.8%PRS 43.6%
-
CSI 1.2rCSI 3.3%PRS 64.0%
-
CSI 1.6rCSI 3.4%PRS 55.4%
-
CSI 1.6rCSI 2.6%PRS 42.0%
-
CSI 1.6rCSI 2.5%PRS 51.1%
-
CSI 1.6rCSI 2.2%PRS 42.7%
-
CSI 1.9rCSI 4.6%PRS 26.0%
-
CSI 2.0rCSI 3.3%PRS 46.2%
-
CSI 2.0rCSI 2.9%PRS 45.6%
-
CSI 2.0rCSI 8.7%PRS 57.8%
-
CSI 2.0rCSI 1.7%PRS 42.0%
-
CSI 2.1rCSI 9.6%PRS 61.3%
-
CSI 2.1rCSI 5.1%PRS 46.9%
-
CSI 2.2rCSI 8.4%PRS 60.0%
-
CSI 2.2rCSI 3.3%PRS 57.1%
-
CSI 2.2rCSI 2.3%PRS 46.7%
-
CSI 2.2rCSI 3.5%PRS 51.0%
-
CSI 2.3rCSI 3.4%PRS 58.1%
-
CSI 2.4rCSI 7.8%PRS 40.5%
-
CSI 2.5rCSI 5.8%PRS 51.9%
-
CSI 2.5rCSI 2.3%PRS 42.2%
-
CSI 2.6rCSI 15.2%PRS 28.0%
-
CSI 2.6rCSI 19.4%PRS 61.3%
-
CSI 2.7rCSI 4.4%PRS 34.8%
-
CSI 2.8rCSI 6.6%PRS 53.4%
-
CSI 2.8rCSI 4.1%PRS 41.1%
-
CSI 2.8rCSI 5.0%PRS 49.3%
-
CSI 2.9rCSI 4.0%PRS 46.6%
-
CSI 3.0rCSI 4.6%PRS 41.5%
-
CSI 3.0rCSI 16.9%PRS 65.8%
-
CSI 3.2rCSI 8.2%PRS 46.4%
-
CSI 3.2rCSI 45.6%PRS 74.5%
-
CSI 3.2rCSI 6.8%PRS 56.0%
-
CSI 3.3rCSI 3.6%PRS 44.7%
-
CSI 3.4rCSI 9.7%PRS 67.8%
-
CSI 3.4rCSI 15.1%PRS 39.6%
-
CSI 3.7rCSI 5.4%PRS 51.7%
-
CSI 3.7rCSI 9.3%PRS 37.7%
-
CSI 3.7rCSI 14.1%PRS 35.5%
-
CSI 3.8rCSI 6.7%PRS 56.7%
-
CSI 3.8rCSI 4.7%PRS 43.6%
-
CSI 3.9rCSI 7.4%PRS 61.1%
-
CSI 4.0rCSI 9.2%PRS 39.9%
-
CSI 4.1rCSI 8.4%PRS 39.3%
-
CSI 4.1rCSI 4.8%PRS 44.8%
-
CSI 4.3rCSI 36.7%PRS 43.6%
-
CSI 4.3rCSI 9.6%PRS 27.4%
-
CSI 4.4rCSI 5.1%PRS 31.9%
-
CSI 4.5rCSI 16.1%PRS 54.3%
-
CSI 4.7rCSI 7.5%PRS 28.8%
-
CSI 4.7rCSI 13.8%PRS 40.2%
-
CSI 4.7rCSI 49.8%PRS 42.9%
-
CSI 4.9rCSI 3.2%PRS 45.0%
-
CSI 5.0rCSI 12.3%PRS 39.1%
-
CSI 5.0rCSI 10.9%PRS 61.0%
-
CSI 5.2rCSI 6.9%PRS 45.3%
-
CSI 5.3rCSI 4.7%PRS 40.3%
-
CSI 5.3rCSI 14.8%PRS 55.7%
-
CSI 5.3rCSI 7.8%PRS 43.8%
-
CSI 5.7rCSI 13.2%PRS 67.3%
-
CSI 5.7rCSI 28.0%PRS 52.3%
-
CSI 5.7rCSI 4.4%PRS 41.2%
-
CSI 5.8rCSI 9.2%PRS 35.4%
-
CSI 6.0rCSI 9.5%PRS 44.4%
-
CSI 6.1rCSI 7.0%PRS 51.9%
-
CSI 6.2rCSI 8.3%PRS 49.1%
-
CSI 6.2rCSI 17.0%PRS 38.1%
-
CSI 6.3rCSI 44.9%PRS 47.7%
-
CSI 6.4rCSI 33.5%PRS 56.1%
-
CSI 7.2rCSI 23.3%PRS 43.6%
-
CSI 7.2rCSI 20.4%PRS 41.1%
-
CSI 7.3rCSI 10.0%PRS 53.6%
-
CSI 7.4rCSI 7.8%PRS 40.7%
-
CSI 7.6rCSI 38.0%PRS 51.4%
-
CSI 7.6rCSI 10.5%PRS 40.6%
-
CSI 7.7rCSI 24.7%PRS 38.2%
-
CSI 7.9rCSI 15.1%PRS 57.5%
-
CSI 8.3rCSI 13.5%PRS 39.8%
-
CSI 8.4rCSI 8.1%PRS 41.6%
-
CSI 8.5rCSI 9.0%PRS 56.3%
-
CSI 8.6rCSI 47.0%PRS 45.3%
-
CSI 9.1rCSI 23.8%PRS 40.0%
-
CSI 9.2rCSI 37.1%PRS 39.7%
-
CSI 9.2rCSI 7.6%PRS 39.6%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 1097495277
Symbol: MECOM_HUMAN
Name: Ecotropic virus integration site 1 protein homolog
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 2115646
Title: Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts.
PubMed ID: 2115646
PubMed ID: 8643684
Title: Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
PubMed ID: 8643684
PubMed ID: 11050005
Title: A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
PubMed ID: 11050005
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 17974005
Title: The full-ORF clone resource of the German cDNA consortium.
PubMed ID: 17974005
PubMed ID: 16641997
Title: The DNA sequence, annotation and analysis of human chromosome 3.
PubMed ID: 16641997
DOI: 10.1038/nature04728
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8313895
Title: Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
PubMed ID: 8313895
PubMed ID: 8700545
Title: Structurally altered Evi-1 protein generated in the 3q21q26 syndrome.
PubMed ID: 8700545
PubMed ID: 9665135
Title: The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
PubMed ID: 9665135
DOI: 10.1038/27945
PubMed ID: 10856240
Title: The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
PubMed ID: 10856240
PubMed ID: 11568182
Title: Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
PubMed ID: 11568182
PubMed ID: 15897867
Title: Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
PubMed ID: 15897867
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 16462766
Title: Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.
PubMed ID: 16462766
PubMed ID: 18220336
Title: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
PubMed ID: 18220336
DOI: 10.1021/pr0705441
PubMed ID: 19767769
Title: Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells.
PubMed ID: 19767769
DOI: 10.1038/onc.2009.288
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 22939622
Title: Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity.
PubMed ID: 22939622
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 25218447
Title: Uncovering global SUMOylation signaling networks in a site-specific manner.
PubMed ID: 25218447
DOI: 10.1038/nsmb.2890
PubMed ID: 26581901
Title: Mutations in MECOM, encoding oncoprotein EVI1, cause radioulnar synostosis with amegakaryocytic thrombocytopenia.
PubMed ID: 26581901
PubMed ID: 25772364
Title: SUMO-2 orchestrates chromatin modifiers in response to DNA damage.
PubMed ID: 25772364
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
Sequence Information:
- Length: 1230
- Mass: 138136
- Checksum: 49E9B7CBCD422042
- Sequence:
MRSKGRARKL ATNNECVYGN YPEIPLEEMP DADGVASTPS LNIQEPCSPA TSSEAFTPKE GSPYKAPIYI PDDIPIPAEF ELRESNMPGA GLGIWTKRKI EVGEKFGPYV GEQRSNLKDP SYGWEILDEF YNVKFCIDAS QPDVGSWLKY IRFAGCYDQH NLVACQINDQ IFYRVVADIA PGEELLLFMK SEDYPHETMA PDIHEERQYR CEDCDQLFES KAELADHQKF PCSTPHSAFS MVEEDFQQKL ESENDLQEIH TIQECKECDQ VFPDLQSLEK HMLSHTEERE YKCDQCPKAF NWKSNLIRHQ MSHDSGKHYE CENCAKVFTD PSNLQRHIRS QHVGARAHAC PECGKTFATS SGLKQHKHIH SSVKPFICEV CHKSYTQFSN LCRHKRMHAD CRTQIKCKDC GQMFSTTSSL NKHRRFCEGK NHFAAGGFFG QGISLPGTPA MDKTSMVNMS HANPGLADYF GANRHPAGLT FPTAPGFSFS FPGLFPSGLY HRPPLIPASS PVKGLSSTEQ TNKSQSPLMT HPQILPATQD ILKALSKHPS VGDNKPVELQ PERSSEERPF EKISDQSESS DLDDVSTPSG SDLETTSGSD LESDIESDKE KFKENGKMFK DKVSPLQNLA SINNKKEYSN HSIFSPSLEE QTAVSGAVND SIKAIASIAE KYFGSTGLVG LQDKKVGALP YPSMFPLPFF PAFSQSMYPF PDRDLRSLPL KMEPQSPGEV KKLQKGSSES PFDLTTKRKD EKPLTPVPSK PPVTPATSQD QPLDLSMGSR SRASGTKLTE PRKNHVFGGK KGSNVESRPA SDGSLQHARP TPFFMDPIYR VEKRKLTDPL EALKEKYLRP SPGFLFHPQM SAIENMAEKL ESFSALKPEA SELLQSVPSM FNFRAPPNAL PENLLRKGKE RYTCRYCGKI FPRSANLTRH LRTHTGEQPY RCKYCDRSFS ISSNLQRHVR NIHNKEKPFK CHLCDRCFGQ QTNLDRHLKK HENGNMSGTA TSSPHSELES TGAILDDKED AYFTEIRNFI GNSNHGSQSP RNVEERMNGS HFKDEKALVT SQNSDLLDDE EVEDEVLLDE EDEDNDITGK TGKEPVTSNL HEGNPEDDYE ETSALEMSCK TSPVRYKEEE YKSGLSALDH IRHFTDSLKM RKMEDNQYSE AELSSFSTSH VPEELKQPLH RKSKSQAYAM MLSLSDKESL HSTSHSSSNV WHSMARAAAE SSAIQSISHV
Genular Protein ID: 3115095008
Symbol: C7FEN9_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Sequence Information:
- Length: 1051
- Mass: 118335
- Checksum: 3270955E25D99D51
- Sequence:
MKSEDYPHET MAPDIHEERQ YRCEDCDQLF ESKAELADHQ KFPCSTPHSA FSMVEEDFQQ KLESENDLQE IHTIQECKEC DQVFPDLQSL EKHMLSHTEE REYKCDQCPK AFNWKSNLIR HQMSHDSGKH YECENCAKVF TDPSNLQRHI RSQHVGARAH ACPECGKTFA TSSGLKQHKH IHSSVKPFIC EVCHKSYTQF SNLCRHKRMH ADCRTQIKCK DCGQMFSTTS SLNKHRRFCE GKNHFAAGGF FGQGISLPGT PAMDKTSMVN MSHANPGLAD YFGANRHPAG LTFPTAPGFS FSVPGLFPSG LYHRPPLIPA SSPVKGLSST EQTNKSQSPL MTHPQILPAT QDILKALSKH PSVGDNKPVE LQPERSSEER PFEKISDQSE SSDLDDVSTP SGSDLETTSG SDLESDIESD KEKFKENGKM FKDKVSPLQN LASINNKKEY SNHSIFSPSL EEQTAVSGAV NDSIKAIASI AEKYFGSTGL VGLQDKKVGA LPYPSMFPLP FFPAFSQSMY PFPDRDLRSL PLKMEPQSPG EVKKLQKGSS ESPFDLTTKR KDEKPLTPVP SKPPVTPATS QDQPLDLSMG SRSRASGTKL TEPRKNHVFG GKKGSNVESR PASDGSLQHA RPTPFFMDPI YRVEKRKLTD PLEALKEKYL RPSPGFLFHP QFQLPDQRTW MSAIENMAEK LESFSALKPE ASELLQSVPS MFNFRAPPNA LPENLLRKGK ERYTCRYCGK IFPRSANLTR HLRTHTGEQP YRCKYCDRSF SISSNLQRHV RNIHNKEKPF KCHLCYRCFG QQTNLDRHLK KHENGNMSGT ATSSPHSELE STGAILDDKE DAYFTEIRNF IGNSNHGSQS PRNVEERMNG SHFKEEKALV PSQNSDLLDD EEVEDEVLLD EEDEDYDITG KTGKEPVTSN LHEGNPEDDY EETSALEMSC KTSPVRYKEE EYKSGLSALD HIRHFTDSLK MRKMEDNQYS EAELSSFSTS HVPEELKQPL HRKSKSQAYA MMLSLSDKES LHSTSHSSSN VWHSMARAAA ESSAIQSISH V
Genular Protein ID: 2796166744
Symbol: A0A0C3SFZ7_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11237011
Title: Initial sequencing and analysis of the human genome.
PubMed ID: 11237011
DOI: 10.1038/35057062
PubMed ID: 15496913
Title: Finishing the euchromatic sequence of the human genome.
PubMed ID: 15496913
DOI: 10.1038/nature03001
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 16641997
Title: The DNA sequence, annotation and analysis of human chromosome 3.
PubMed ID: 16641997
DOI: 10.1038/nature04728
PubMed ID: 18220336
Title: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
PubMed ID: 18220336
DOI: 10.1021/pr0705441
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
PubMed ID: 25218447
Title: Uncovering global SUMOylation signaling networks in a site-specific manner.
PubMed ID: 25218447
PubMed ID: 25772364
Title: SUMO-2 orchestrates chromatin modifiers in response to DNA damage.
PubMed ID: 25772364
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
Sequence Information:
- Length: 1052
- Mass: 118404
- Checksum: EBD71A48C4BE480F
- Sequence:
MKSEDYPHET MAPDIHEERQ YRCEDCDQLF ESKAELADHQ KFPCSTPHSA FSMVEEDFQQ KLESENDLQE IHTIQECKEC DQVFPDLQSL EKHMLSHTEE REYKCDQCPK AFNWKSNLIR HQMSHDSGKH YECENCAKQV FTDPSNLQRH IRSQHVGARA HACPECGKTF ATSSGLKQHK HIHSSVKPFI CEVCHKSYTQ FSNLCRHKRM HADCRTQIKC KDCGQMFSTT SSLNKHRRFC EGKNHFAAGG FFGQGISLPG TPAMDKTSMV NMSHANPGLA DYFGANRHPA GLTFPTAPGF SFSFPGLFPS GLYHRPPLIP ASSPVKGLSS TEQTNKSQSP LMTHPQILPA TQDILKALSK HPSVGDNKPV ELQPERSSEE RPFEKISDQS ESSDLDDVST PSGSDLETTS GSDLESDIES DKEKFKENGK MFKDKVSPLQ NLASINNKKE YSNHSIFSPS LEEQTAVSGA VNDSIKAIAS IAEKYFGSTG LVGLQDKKVG ALPYPSMFPL PFFPAFSQSM YPFPDRDLRS LPLKMEPQSP GEVKKLQKGS SESPFDLTTK RKDEKPLTPV PSKPPVTPAT SQDQPLDLSM GSRSRASGTK LTEPRKNHVF GGKKGSNVES RPASDGSLQH ARPTPFFMDP IYRVEKRKLT DPLEALKEKY LRPSPGFLFH PQFQLPDQRT WMSAIENMAE KLESFSALKP EASELLQSVP SMFNFRAPPN ALPENLLRKG KERYTCRYCG KIFPRSANLT RHLRTHTGEQ PYRCKYCDRS FSISSNLQRH VRNIHNKEKP FKCHLCDRCF GQQTNLDRHL KKHENGNMSG TATSSPHSEL ESTGAILDDK EDAYFTEIRN FIGNSNHGSQ SPRNVEERMN GSHFKDEKAL VTSQNSDLLD DEEVEDEVLL DEEDEDNDIT GKTGKEPVTS NLHEGNPEDD YEETSALEMS CKTSPVRYKE EEYKSGLSAL DHIRHFTDSL KMRKMEDNQY SEAELSSFST SHVPEELKQP LHRKSKSQAY AMMLSLSDKE SLHSTSHSSS NVWHSMARAA AESSAIQSIS HV